Armata Pharmaceuticals, Inc.

AMEX•ARMP

CEO: Dr. Deborah L. Birx M.D.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 1994-05-20

Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.

Contact Information

5005 McConnell Avenue, Los Angeles, CA, 90066, United States

310-665-2928

www.armatapharma.com

Market Cap

$386.84M

P/E (TTM)

-2.2

Dividend Yield

52W High

$16.34

52W Low

$0.90

52W Range

63%

Rank65Top 96.0%

1.6

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Weak • 1.6 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$1.09M+0.00%

4-Quarter Trend

EPS

-$3.43+0.00%

4-Quarter Trend

FCF

-$6.73M+0.00%

4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Cash Position Improved Cash and equivalents reached $14.8M; net cash used in operations improved $10.5M for nine months ended September 30.

R&D Expenses Decreased Total research and development expenses fell $8.3M for nine months 2025 versus 2024, reflecting cost management efforts.

AP-SA02 Clinical Results Positive AP-SA02 combined with BAT showed higher, earlier cure rate versus placebo in complicated SAB Phase 2a study.

New Financing Secured Secured August 2025 Credit Agreement providing $15.0M loan to support operations and development activities.

Risk Factors

Going Concern Substantial Doubt Accumulated deficit reached $377.2M; current cash insufficient to fund operations for next twelve months period.

Net Loss Widened Substantially Nine month net loss increased 130.1% to $49.5M, driven by $15.2M loss on Convertible Loan fair value change.

Current Liabilities Increased Total current liabilities surged to $139.95M, largely due to reclassification of Convertible Loan portion.

Future Capital Requirements Must raise additional capital via equity, debt, or grants; success not assured on favorable terms.

Outlook

Advance AP-SA02 Pivotal Trial Plans advancing AP-SA02 into pivotal Phase 3 trial in 2026, subject to FDA feedback on superiority design.

AP-PA02 NCFB Resumption May resume AP-PA02 NCFB clinical development, including Phase 3 trial, contingent upon securing sufficient future funding.

Explore AP-PA02 New Indications Exploring development of Pseudomonas phage cocktail for acute ventilator-associated pneumonia and severe infections.

Peer Comparison

Revenue (TTM)

GNFT

$126.71M

+9.8%

CDXS

$70.39M

+18.6%

SGMO

$39.55M

-31.6%

Gross Margin (Latest Quarter)

GNFT

100.0%

+0.0pp

OABI

99.9%

-209.2pp

IRD

99.7%

-0.4pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
SLS	$599.68M	-24.0	-63.1%	1.3%
GNFT	$445.68M	-11.1	-63.7%	64.1%
NAUT	$424.62M	-7.2	-33.6%	15.7%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

30.3%

Strong Growth

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:May 7, 2026

EPS:-

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data